Publications scientifiques

Depuis le 31/03/2025
  1. Gloves Standards and Occupational Exposure to Antineoplastic Drugs in the European Context.
    Swierczynski G, Canal-Raffin M, Tuduri L.
    Health Sci Rep. 2025
  2. Changes in the Ambulatory Use of Antibiotics in France Due to the COVID-19 Pandemic in 2020-2022: A Nationwide Time-Series Analysis.
    Rousselot N, Brayan T, Dumartin C, Clément M, Pariente A.
    Ann Fam Med. 2025
  3. Major Adverse Cardiovascular Events Related to JAK Inhibitors: A Disproportionality Analysis Using the WHO Global Individual Case Safety Database.
    Di Napoli R, Richez C, Scavone C, Singier A, Demorgues M, Mascolo A, Capuano A, Salvo F.
    Drug Saf. 2025
  4. Second primary cancers and hormonal therapies for prostate cancer: A nested case-control study.
    Scailteux LM, Bezin J, Gundelwein M, Edeline J, Oger E, Balusson F, Pariente A.
    Fundam Clin Pharmacol. 2025
  5. Guidelines and Best Practices for the Use of Targeted Maximum Likelihood and Machine Learning When Estimating Causal Effects of Exposures on Time-To-Event Outcomes.
    Talbot D, Diop A, Mésidor M, Chiu Y, Sirois C, Spieker AJ, Pariente A, Noize P, Simard M, Luque Fernandez MA, Schomaker M, Fujita K, Gnjidic D, Schnitzer ME.
    Stat Med. 2025
  6. Are Causal Statements Reported in Pharmacovigilance Disproportionality Analyses Using Individual Case Safety Reports Exaggerated in Related Citations? A Meta-epidemiological Study.
    Bernardeau C, Revol B, Salvo F, Fusaroli M, Raschi E, Cracowski JL, Roustit M, Khouri C.
    Drug Saf. 2025
  7. Psychoactive cocktail consumption on Reunion Island: A case report.
    Guyon J, Maillot A, Bastard S, Weisse F, Daveluy A, Mété D.
    J Anal Toxicol. 2025
  8. Impact of psychedelics on craving in addiction: A systematic review.
    Chapron SA, Bonazzi G, Di Lodovico L, de Ternay J, Landmann C, Nourredine M, Salvo F, Sessa B, Das R, Rolland B, Garcia-Romeu A, Auriacombe M.
    J Psychopharmacol. 2025
  9. Suicide and suicide attempt in users of GLP-1 receptor agonists: a nationwide case-time-control study.
    Bezin J, Bénard-Laribière A, Hucteau E, Tournier M, Montastruc F, Pariente A, Faillie JL.
    EClinicalMedicine. 2024
  10. Successful Linkage of Electronic Medical Records and National Health Data System in Type 2 Diabetes Research: Methodological Insights and Implications.
    Goff RL, Brice S, Contini A, Boussac M, Souche A, Belloc F, Coulombel N, Collin C, Gouverneur A, Molimard M.
    Pharmacoepidemiol Drug Saf. 2025
  11. Ethics and clinical research: How can the Ethics Committees (CPPs) and Committees for Research Ethics (CER) evolve?
    Berdaï D, Guérin A, Pérol D, Girault C, Molimard M, Amiel P, Beaussier H, Bertoye PH, Cornu C, Deplanque D, Dreyfuss D, Duchossoy L, Fouret C, Haaser T, Le Louarn A, Rifai S, Thierry JP.
    Therapie. 2025
  12. Shaping the future of pharmacoepidemiology in France: Recommendations from the SFPT Pharmacoepidemiology Working Group.
    Soeiro T, Allouchery M, Bene J, Bezin J, Dolladille C, Faillie JL, Grimaldi L, Kaguelidou F, Khouri C, Lafaurie M, Largeau B, Montastruc F, Morin L, Scailteux LM, Pariente A; SFPT Pharmacoepidemiology Working Group.
    Therapie. 2024
  13. The reporting of disproportionality analysis in pharmacovigilance: spotlight on the READUS-PV guideline.
    Fusaroli M, Salvo F, Khouri C, Raschi E.
    Front Pharmacol. 2024
  14. Early Detection of Hearing Impairment Signals Post-mRNA COVID-19 Vaccination: A Disproportionality Analysis Study on French Pharmacovigilance Database.
    Boulefaa D, Bagheri H, Salvo F, Rabier MB, Geniaux H, Lepelley M, Rocher F, Mahe J, Grandvillemuin A, Thai-Van H.
    Drug Saf. 2025
  15. The enhanced national pharmacovigilance system implemented for COVID-19 vaccines in France: A 2-year experience report.
    Crommelynck S, Grandvuillemin A, Ferard C, Mounier C, Gault N, Pierron E, Jacquot B, Vaillant T, Chatelet IPD, Jacquet A, Salvo F, Alt M, Bagheri H, Micallef J, Pariente A, Gautier S, Valnet-Rabier MB, Atzenhoffer M, Lepelley M, Cottin J, Lacroix I, Gras V, Massy N, Dhanani A, Vella P, Shaim Y, Baril L, Jonville-Béra AP, Benkebil M; 30 French Regional Pharmacovigilance Centres.
    Therapie. 2024
  16. ASOS, a national monitoring study to assess narcotic prescriptions and indications in France since 2001.
    Perri-Plandé J, Miremont-Salamé G, Lapeyre-Mestre M, Perino J, Gibaja V, Daveluy A; French Addictovigilance Network.
    Therapie. 2024
  17. From regional signal to alert in addictovigilance.
    Daveluy A, Perino J, Gibaja V, Le Boisselier R, Batisse A, Miremont-Salamé G, Peyré A, Boucher A, Frauger E, Micallef J, Peyrière H.
    Therapie. 2024
  18. Éthique et recherche clinique : quelles évolutions pour les CPP et les comités d’éthique de la recherche ?
    Berdaï D, Guérin A, Pérol D, Girault C, Molimard M, Amiel P, Beaussier H, Bertoye PH, Cornu C, Deplanque D, Dreyfuss D, Duchossoy L, Fouret C, Haaser T, Le Louarn A, Rifai S, Thierry JP.
    Therapie. 2024
  19. Inputs of pharmacoepidemiology in addictovigilance: How do they fit together?
    Soeiro T, Daveluy A, Victorri-Vigneau C, Lapeyre-Mestre M, Micallef J.
    Therapie. 2024
  20. Correction to "Impact of liquid sublingual immunotherapy on asthma onset and progression in patients with allergic rhinitis: a nationwide population-based study (EfficAPSI study)" [The Lancet Regional Health - Europe 41 (2024) 100915]
    Demoly P, Molimard M, Bergmann JF, Delaisi B, Gouverneur A, Vadel J, Collin C, Girard L, Scurati S, Devillier P.
    Lancet Reg Health Eur. 2024